source
- Argenx to acquire Forte Biosciences for $2.2 billion, adding anti‑CD122 antibody programArgenx announced a $2.2 billion cash transaction to purchase Forte Biosciences, a biotech focused on autoimmune therapies. The acquisition brings Forte's anti‑CD122 monoclonal antibody, which is c…
- Argenx to acquire Forte Biosciences for $2.2 billion, securing phase-2 vitiligo antibody FB102Argenx announced it will buy Forte Biosciences for $2.2 billion, gaining access to FB102, an anti‑CD122 antibody currently in phase‑2 trials for vitiligo and celiac disease. In a recent phase 1b s…